Journal of Diabetes最新文献

{"title":"The rising prevalence of type 2 diabetes among the youth in southern India—An ancillary analysis of the Secular TRends in DiabEtes in India (STRiDE-I) study","authors":"Arun Nanditha,&nbsp;Priscilla Susairaj,&nbsp;Krishnamoorthy Satheesh,&nbsp;Arun Raghavan,&nbsp;Chamukuttan Snehalatha,&nbsp;Ambady Ramachandran","doi":"10.1111/1753-0407.13576","DOIUrl":"10.1111/1753-0407.13576","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>We studied the prevalence and incidence of type 2 diabetes (T2DM) and its associated risk factors in younger (20 and 39 years) and older individuals (≥40 years) over a 10-year period.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Epidemiological surveys in 2006 (<i>n</i> = 7066) and 2016 (<i>n</i> = 9848) were conducted in similar urban and rural locations of southern India among people aged ≥20 years. Diagnosis of T2DM was made using World Health Organization criteria. Self-reported diabetes was verified from medical records. Age and gender standardized prevalence and incidence rates, percentage change in obesity, hypertension, and dyslipidemia were calculated. Prevalence ratios (PR) were calculated using Poisson regression analyses. Primary study was registered on www.ClinicalTrials.gov. Identifier: NCT03490136.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In 10 years, the prevalence of T2DM increased in younger (7.8% vs. 4.5%, <i>p</i> &lt; 0.0001) and older individuals (34% vs. 28.4%, <i>p</i> &lt; 0.0001). After adjusting for age, family history of diabetes, and waist circumference, younger individuals showed a higher percentage increase in prevalence than the older group (PR = 1.36 [95% confidence interval [CI], 1.14–1.62], <i>p</i> = 0.001) versus (PR = 1.11 [95% CI, 1.02–1.20], <i>p</i> = 0.02). Increase in rates of obesity and dyslipidemia was also higher in the younger than in the older individuals. In 10 years, incidence of T2DM increased by 120% (1.1% vs. 0.5%, <i>p</i> &lt; 0.0001) and 150% (5% vs. 2%, <i>p</i> &lt; 0.0001) in the younger and older individuals, respectively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Higher percentage increase in prevalence of T2DM was seen among younger individuals over a 10-year period. Obesity and family history of diabetes were shown to be the primary contributing factors for the rise in prevalence.</p>\u0000 \u0000 <div>\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure>\u0000 </div>\u0000 </section>\u0000 </div>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"16 7","pages":""},"PeriodicalIF":3.0,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11200006/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141454188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between red cell distribution width/serum albumin ratio and diabetic kidney disease","authors":"Jiaqi Chen,&nbsp;Daguan Zhang,&nbsp;Depu Zhou,&nbsp;Zhijuan Dai,&nbsp;Jie Wang","doi":"10.1111/1753-0407.13575","DOIUrl":"10.1111/1753-0407.13575","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Previous studies have shown that the red cell distribution width (RDW)/serum albumin ratio (RA) is an integrative and new inflammatory marker. RA is associated with clinical outcomes in a variety of diseases, but the clinical value of RDW/RA in the assessment of diabetic kidney disease (DKD) has not been elucidated. We examined the link between diabetic RA and DKD while controlling for a wide variety of possible confounders.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Retrospective cohort analysis of the National Health and Nutrition Examination Survey (NHANES: 2009–2018) database from the Second Affiliated Hospital and Yuying Children's Hospital and the Wenzhou Medical University (WMU) database was conducted. Multivariate logistic regression analysis was used to assess the association between RA and DKD.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Overall, 4513 diabetic patients from the NHANES database (<i>n</i> = 2839) and the WMU (<i>n</i> = 1412) were included in this study; 974 patients were diagnosed with DKD in NHANES and 462 in WMU. In the NHANES cohort, diabetes mellitus (DM) patients with higher RA level had a higher risk of DKD (odds ratio = 1.461, 95% confidence interval: 1.250–1.707, <i>p</i> &lt; 0.00001). After adjusting for confounders and propensity score-matched (PSM) analysis, both shown RA levels were independently linked to DKD (<i>p</i>_Adjust = 0.00994, <i>p</i>_PSM = 0.02889). Similar results were also observed in the WMU cohort (<i>p</i> &lt; 0.00001).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The study observes that the RA was an independent predictor of DKD in DM patients. The RA, a biomarker that is cost-effective and easy-to-access, may have potential for risk stratification of DKD.</p>\u0000 \u0000 <div>\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure>\u0000 </div>\u0000 </section>\u0000 </div>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"16 7","pages":""},"PeriodicalIF":3.0,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11200132/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141454186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What will we see in diabetes in the next 10 years?","authors":"Zachary T. Bloomgarden","doi":"10.1111/1753-0407.13594","DOIUrl":"10.1111/1753-0407.13594","url":null,"abstract":"&lt;p&gt;The theme of growing numbers of persons with diabetes in relation to the aging of the population and to worsening obesity are factors brought up by Ellliott Joslin more than six decades ago in an article entitled “Diabetes in the Future”&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt;—but it remains daunting to face the reality of a progressive threefold increase from approximately 150 million in 2000 to more than 500 million cases today, with projections of a total of 700–800 million persons with diabetes by 2045.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; The greatest increases will be in South-East Asia, from 90 to over 150 million, and in the Middle East and North Africa, from approximately 70 to 140 million, albeit with the Western Pacific countries increasing from 200 million to 260 million persons to remain the largest region of persons with diabetes.&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;Diabetes prevalence increases with increasing age and increasing degrees of obesity, with both of these factors projected to play important roles in the growth of diabetes over the coming decades. The prevalence of diabetes increases from &lt;5% before the age of 35 to 5%–10% from age 35–50 and to nearly 15% in middle-income countries, remaining around 10% from age 50–80 in low-income countries but increasing to &gt;20% in middle-income countries and to &gt;25% in high-income countries at ages 65 and over.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; This becomes particularly important when we consider world population trends. The United Nations' projection of World Population Prospects showed that in 1950, there were fewer than 200 million persons aged 65 and over; this number began to increase gradually and by 2000, reached approximately 500 million, with projections that in the year 2100, there will be approximately 2.5 billion persons in this age group, equaling the number of persons aged less than 20 and 45–64, with the number of persons aged 20–44 being relatively static at an additional 3.5 billion.&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt; The same dataset shows that in China, the largest part of the Western Pacific region, the number of persons aged 20–44 is likely to have peaked around 2010, with projections of a decline in this age group from nearly 600 billion to approximately 300 billion in the year 2100, equaling the number of persons aged 65 and over and exceeding that in the 45–65-year-old and &lt;20-year-old age groups.&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt; Taken together, the higher prevalence of diabetes with increasing age along with the increasing numbers of persons at greater ages implies that older persons contribute disproportionately to the population with diabetes, comprising a proportion increasing from 30% to 40% of persons with diabetes in the United States from 1980 to 2010.&lt;span&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;In addition to the aging of the population, the growth in numbers of persons with increasing degrees of obesity is an evident and worrisome characteristic; virtually every high-income country is seeing increases in pr","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"16 6","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1753-0407.13594","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141417035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent drug development of dorzagliatin, a new glucokinase activator, with the potential to treat Type 2 diabetes: A review study","authors":"Yu Jiang,&nbsp;Luyao Wang,&nbsp;Zhenhua Dong,&nbsp;Baotian Xia,&nbsp;Shuguang Pang","doi":"10.1111/1753-0407.13563","DOIUrl":"10.1111/1753-0407.13563","url":null,"abstract":"<p>Type 2 diabetes mellitus (T2DM) is a complicated disease related to metabolism that results from resistance to insulin and sustained hyperglycemia. Traditional antidiabetic drugs cannot meet the demand of different diabetes patients for reaching the glycemic targets; thus, the identification of new antidiabetic drugs is urgently needed for the treatment of T2DM to enhance glycemic control and the prognosis of patients suffering from T2DM. Recently, glucokinase (GK) has attracted much attention and is considered to be an effective antidiabetic agent. Glucokinase activators (GKA) represented by dorzagliatin could activate GK and mimic its function that triggers a counter-regulatory response to blood glucose changes. Dorzagliatin has shown great potential for glycemic control in diabetic patients in a randomized, double-blind, placebo-controlled Phase 3 trial (SEED study) and had a favorable safety profile and was well tolerated (DAWN study). In the SEED study, dorzagliatin significantly reduced glycosylated hemoglobin (HbA1c) by 1.07% and postprandial blood glucose by 2.83 mol/L, showing the great potential of this drug to control blood glucose in diabetic patients, with good safety and good tolerance. An extension of the SEED study, the DREAM study, confirmed that dorzagliatin monotherapy significantly improved 24-h glucose variability and increased time in range (TIR) to 83.7% over 46 weeks. Finally, the clinical study of dorzagliatin combined with metformin (DAWN study) confirmed that dorzagliatin could significantly reduce HbA1c by 1.02% and postprandial blood glucose by 5.45 mol/L. The current review summarizes the development of GK and GKA, as well as the prospects, trends, applications, and shortcomings of these treatments, especially future directions of clinical studies of dorzagliatin.</p><p>\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"16 6","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1753-0407.13563","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141086333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between the stress–hyperglycemia ratio and all-cause mortality in community-dwelling populations: An analysis of the National Health and Nutrition Examination Survey (NHANES) 1999–2014","authors":"Shifeng Qiu,&nbsp;Xiaocong Liu,&nbsp;Li Lei,&nbsp;Hongbin Liang,&nbsp;Xue Li,&nbsp;Yutian Wang,&nbsp;Chen Yu,&nbsp;Xiaobo Li,&nbsp;Yongzhen Tang,&nbsp;Juefei Wu,&nbsp;Yuegang Wang,&nbsp;Daogang Zha,&nbsp;Xuewei Liu,&nbsp;Min Xiao,&nbsp;Jiancheng Xiu","doi":"10.1111/1753-0407.13567","DOIUrl":"10.1111/1753-0407.13567","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Reportedly, the stress–hyperglycemia ratio (SHR) is closely associated with poor prognosis in patients with severe acute disease. However, the community-dwelling may also be in a state of stress due to environmental exposure. Our study aimed to explore the association between SHR and all-cause mortality in the community-dwelling population.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A total of 18 480 participants were included out of 82 091 from the NHANES 1999–2014 survey. The Kaplan–Meier survival analyses were used to assess the disparities in survival rates based on SHR, and the log-rank test was employed to investigate the distinctions between groups. The multivariate Cox regression analysis and restricted cubic spline (RCS) analysis were performed to assess the association of SHR with all-cause mortality. A subgroup analysis was also conducted.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 3188 deaths occurred during a median follow-up period of 11.0 (7.7; 15.4) years. The highest risk for all-cause mortality was observed when SHR≤ 0.843 or SHR ≥0.986 (log-rank <i>p</i> &lt; .001). After adjusting for the confounding factors, compared with subjects in the second SHR quartile (Q2), participants in the highest (Q4, adjusted hazard ratio [HR] 1.49, 95% confidence interval [CI] 1.28–1.73) and lowest quartiles (Q1, adjusted HR 1.37, 95% CI 1.16–1.60) have a higher probability of all-cause death. The RCS observed a dose-response U-shaped association between SHR and all-cause mortality. The U-shaped association between SHR and all-cause mortality was similar across subgroup analysis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The SHR was significantly associated with all-cause mortality in the community-dwelling population, and the relationship was U-shaped.</p>\u0000 \u0000 <div>\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure>\u0000 </div>\u0000 </section>\u0000 </div>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"16 6","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1753-0407.13567","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141070004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glucagon-like-peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes in diabetes in relation to achieved glycemic control. A Danish nationwide study","authors":"Bochra Zareini,&nbsp;Katrine Kold Sørensen,&nbsp;Ulrik Pedersen-Bjergaard,&nbsp;Emil Loldrup Fosbøl,&nbsp;Lars Køber,&nbsp;Christian Torp-Pedersen","doi":"10.1111/1753-0407.13560","DOIUrl":"10.1111/1753-0407.13560","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Aim&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;To compare the cardiovascular preventive effect associated with glucagon-like-peptide-1 receptor agonists (GLP-1 RA) versus dipeptidyl peptidase-4 inhibitors (DPP-4i) according to the achieved target level of glycated hemoglobin (HbA1c).&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;We used retrospective Danish registries to include type 2 diabetes patients already in metformin treatment initiating GLP-1 RA or DPP-4i between 2007 and 2021. Patients were included 6 months after GLP-1 RA or DPP-4i initiation. The last available HbA1c measurement before inclusion was collected. The achieved HbA1c level was categorized according to a target level below or above 53 mmol/mol (7%). The primary outcome was a composite of nonfatal myocardial infarction, nonfatal stroke, and all-cause death. We used a multivariable Cox proportional hazard model to estimate the effect of HbA1c levels on the outcome among GLP-1 RA users compared to DPP-4i users.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The study included 13 634 GLP-1 RA users (median age 56.9, interquartile range [IQR]: 48.5–65.5; 53% males) and 39 839 DPP-4i users (median age 63.4, IQR: 54.6–71.8; 61% males). The number of GLP-1 RA and DPP-4i users according to achieved HbA1c levels were as follows: HbA1c ≤ 53 mmol/mol (≤7.0%): 3026 (22%) versus 4824 (12%); HbA1c &gt; 53 mmol/mol (&gt;7.0%): 6577 (48%) versus 17 508 (44%); missing HbA1c: 4031 (30%) versus 17 507 (44%). During a median follow-up of 5 years (IQR: 2.6–5.0), 954 GLP-1 RA users experienced the primary outcome compared to 7093 DPP-4i users. The 5-year risk (95% confidence interval [CI]) of the outcome associated with GLP1-RA versus DPP-4i according to HbA1c categories was as follows: HbA1c ≤ 53 mmol/mol: 10.3% (8.2–12.3) versus 24.3% (22.7–25.8); HbA1c &gt; 53 mmol/mol: 16.0% (14.3–17.6) versus 21.1% (20.3–21.9); missing HbA1c: 17.1% (15.7–18.5) versus 25.6% (24.9–26.3). The preventive effect associated with GLP-1 RA versus DPP-4i was significantly enhanced when achieving lower HbA1c levels: HbA1c ≤ 53 mmol/mol: 0.65 (0.52–0.80); HbA1c &gt; 53 mmol/mol: 0.92 (0.83–1.03); missing HbA1c: 0.92 (0.84–1.02) (&lt;i&gt;p&lt;/i&gt; value for interaction &lt;.001).&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusion&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;GLP-1 RA use was associated with a lower rate of major adverse cardiovascular outcomes. The association was stronger in patients achieving the target glycemic level and weaker in patients not achieving the target glycemic level, suggestive of an interaction between achieved HbA1c level and GLP-1 RA.&lt;/p&gt;\u0000 \u0000 ","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"16 6","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1753-0407.13560","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140943459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optogenetic therapeutic strategies for diabetes mellitus","authors":"Xin Deng,&nbsp;Dandan Peng,&nbsp;Yuanfa Yao,&nbsp;Ke Huang,&nbsp;Jinling Wang,&nbsp;Zhihao Ma,&nbsp;Junfen Fu,&nbsp;Yingke Xu","doi":"10.1111/1753-0407.13557","DOIUrl":"10.1111/1753-0407.13557","url":null,"abstract":"<p>Diabetes mellitus (DM) is a common chronic disease affecting humans globally. It is characterized by abnormally elevated blood glucose levels due to the failure of insulin production or reduction of insulin sensitivity and functionality. Insulin and glucagon-like peptide (GLP)-1 replenishment or improvement of insulin resistance are the two major strategies to treat diabetes. Recently, optogenetics that uses genetically encoded light-sensitive proteins to precisely control cell functions has been regarded as a novel therapeutic strategy for diabetes. Here, we summarize the latest development of optogenetics and its integration with synthetic biology approaches to produce light-responsive cells for insulin/GLP-1 production, amelioration of insulin resistance and neuromodulation of insulin secretion. In addition, we introduce the development of cell encapsulation and delivery methods and smart bioelectronic devices for the in vivo application of optogenetics-based cell therapy in diabetes. The remaining challenges for optogenetics-based cell therapy in the clinical translational study are also discussed.</p><p>\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"16 6","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1753-0407.13557","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140943463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"LncRNA SNHG14 silencing attenuates the progression of diabetic nephropathy via the miR-30e-5p/SOX4 axis","authors":"YunXia Wang,&nbsp;JiaJia Yang,&nbsp;Chun Wu,&nbsp;Yuqin Guo,&nbsp;Yuan Ding,&nbsp;Xiujuan Zou","doi":"10.1111/1753-0407.13565","DOIUrl":"10.1111/1753-0407.13565","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Diabetic nephropathy (DN) is a diabetic complication. LncRNAs are reported to participate in the pathophysiology of DN. Here, the function and mechanism of lncRNA <i>small nucleolar RNA host gene</i> <i>14</i> (<i>SNHG14</i>) in DN were explored.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Streptozotocin (STZ)-induced DN mouse models and high glucose (HG)-treated human mesangial cells (MCs) were used to detect <i>SNHG14</i> expression. <i>SNHG14</i> silencing plasmids were applied to examine the function of <i>SNHG14</i> on proliferation and fibrosis in HG-treated MCs. Potential targets of <i>SNHG14</i> were predicted using bioinformatics tools and verified by luciferase reporter, RNA pulldown, and northern blotting assays. The functional role of <i>SNHG14</i> in DN in vivo was detected by injection with adenoviral vector carrying sh-<i>SNHG14</i> into DN mice. Serum creatinine, blood urea nitrogen, blood glucose, 24-h proteinuria, relative kidney weight, and renal pathological changes were examined in DN mice.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p><i>SNHG14</i> expression was elevated in the kidneys of DN mice and HG-treated MCs. <i>SNHG14</i> silencing inhibited proliferation and fibrosis of HG-stimulated MCs. <i>SNHG14</i> bound to <i>miR-30e-5p</i> to upregulate <i>SOX4</i> expression. In rescue assays, <i>SOX4</i> elevation diminished the effects of <i>SNHG14</i> silencing in HG-treated MCs, and <i>SOX4</i> silencing reversed the effects of <i>SNHG14</i> overexpression. In in vivo studies, <i>SNHG14</i> downregulation significantly ameliorated renal injuries and renal interstitial fibrosis in DN mice.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p><i>SNHG14</i> silencing attenuates kidney injury in DN mice and reduces proliferation and fibrotic phenotype of HG-stimulated MCs via the <i>miR-30e-5p</i>/<i>SOX4</i> axis.</p>\u0000 \u0000 <div>\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure>\u0000 </div>\u0000 </section>\u0000 </div>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"16 6","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1753-0407.13565","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140943461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparing long-term outcomes of children treated with new-onset type 2 diabetes in an outpatient versus inpatient setting: A retrospective chart review","authors":"Adesh Ranganna,&nbsp;Wenya Chen,&nbsp;Sean DeLacey,&nbsp;Juan Lado,&nbsp;Laura Levin,&nbsp;Anita Swamy,&nbsp;Monica E. Bianco","doi":"10.1111/1753-0407.13571","DOIUrl":"10.1111/1753-0407.13571","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Early identification and management of pediatric type 2 diabetes mellitus (T2DM) is crucial for improving long-term outcomes. This study aimed to assess if the severity of T2DM at presentation, inferred by the location of treatment initiation (inpatient or outpatient), influences long-term clinical outcomes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A retrospective chart review was conducted on 116 pediatric T2DM patients. Data on treatment initiation location, initial and subsequent glycated hemoglobin (HbA1c) levels, prescribed insulin, and body mass index were collected from electronic medical records.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of the 116 patients, 69 were initially treated in an inpatient setting, and 47 received outpatient treatment. At treatment initiation, the inpatient group had significantly higher HbA1c levels compared to the outpatient group (<i>p</i> &lt; .001), but 3 years after treatment initiation, no significant difference in HbA1c was observed between the two groups (<i>p</i> = .057). Prescribed insulin dosages were higher in the inpatient group at treatment initiation (<i>p</i> &lt; .001) and remained higher after 3 years (<i>p</i> &lt; 0.003) compared to the outpatient group.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Pediatric patients initially treated in an inpatient setting had poorer glycemic control and higher prescribed insulin dosing at baseline. After 3 years, there was no significant difference in HbA1c levels, but patients treated as inpatients continued to have higher prescribed insulin. These findings suggest that the severity of diabetes at initial presentation may affect long-term clinical outcomes in children with T2DM.</p>\u0000 \u0000 <div>\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure>\u0000 </div>\u0000 </section>\u0000 </div>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"16 6","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1753-0407.13571","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140943474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Renal effects and safety between Asian and non-Asian chronic kidney disease and type 2 diabetes treated with nonsteroidal mineralocorticoid antagonists","authors":"Xiaoming Xu,&nbsp;Jing Feng,&nbsp;Yuying Cui,&nbsp;Pingjiang Li,&nbsp;Jianjun Dong,&nbsp;Lin Liao","doi":"10.1111/1753-0407.13566","DOIUrl":"https://doi.org/10.1111/1753-0407.13566","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Asians bear a heavier burden of chronic kidney disease (CKD), a common comorbidity of type 2 diabetes mellitus (T2DM), than non-Asians. Nonsteroidal mineralocorticoid receptor antagonists (MRAs) have garnered attention for their potential advantages in renal outcomes. Nevertheless, the impact on diverse ethnic groups remains unknown.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang database, and clinical trial registries were searched through August 2023 with the following keywords: nonsteroidal MRAs (finerenone, apararenone, esaxerenone, AZD9977, KBP-5074), CKD, T2DM, and randomized controlled trial (RCT). A random effects model was used to calculate overall effect sizes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Seven RCTs with 14 997 participants were enrolled. Nonsteroidal MRAs reduced urinary albumin to creatinine ratio (UACR) significantly more in Asians than non-Asians: (weighted mean difference [WMD], −0.59, 95% CI, −0.73 to −0.45, <i>p</i> &lt; .01) vs (WMD, −0.29, 95% CI, −0.32 to −0.27, <i>p</i> &lt; .01), respectively. The average decline of estimated glomerular filtration rate (eGFR) was similar in Asians and non-Asians (<i>p</i> &gt; .05). Regarding systolic blood pressure (SBP), nonsteroidal MRAs had a better antihypertension performance in Asians (WMD, −5.12, 95% CI, −5.84 to −4.41, <i>p</i> &lt; .01) compared to non-Asians (WMD, −3.64, 95% CI, −4.38 to −2.89, <i>p</i> &lt; .01). A higher incidence of hyperkalemia and eGFR decrease ≥30% was found in Asians than non-Asians (<i>p</i> &lt; .01).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Nonsteroidal MRAs exhibited significant renal benefits by decreasing UACR and lowering SBP in Asian than that of non-Asian patients with CKD and T2DM, without increase of adverse events except hyperkalemia and eGFR decrease ≥30%.</p>\u0000 \u0000 <div>\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure>\u0000 </div>\u0000 </section>\u0000 </div>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"16 6","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1753-0407.13566","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140952971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}